2-[4-(2,8-Dichloro-10,11-dihydro-dibenzo[b,f]thiepin-10-yl)-piperazin-1-yl]-ethanol | 107165-59-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并硫平类
• 英文名称: 2-[4-(2,8-Dichloro-10,11-dihydro-dibenzo[b,f]thiepin-10-yl)-piperazin-1-yl]-ethanol
• 英文别名: 2-[4-(2,8-Dichloro-10,11-dihydrodibenzo[b,f]thiepin-10-yl)-1-piperazinyl]ethanol；2-[4-(3,8-dichloro-5,6-dihydrobenzo[b][1]benzothiepin-5-yl)piperazin-1-yl]ethanol
• CAS: 107165-59-3
• 化学式: C₂₀H₂₂Cl₂N₂OS
• 分子量: 409.379
• InChiKey: RITAQUDKGCYTMA-UHFFFAOYSA-N

物化性质

• 熔点：
  97-101 °C
• 沸点：
  530.8±50.0 °C(Predicted)
• 密度：
  1.344±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.3
• 重原子数：
  26
• 可旋转键数：
  3
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  52
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  2,8,10-Trichloro-10,11-dihydrodibenzothiepin 在 N-羟乙基哌嗪 作用下， 以 氯仿 为溶剂， 反应 7.0h， 以60%的产率得到2-[4-(2,8-Dichloro-10,11-dihydro-dibenzo[b,f]thiepin-10-yl)-piperazin-1-yl]-ethanol
  参考文献：
  名称：

  Potential noncataleptic neuroleptic agents; 2,6-Dichloro-, 2,7-dichloro- and 2,8-dichloro-10-piperazino-10,11-dihydrodibenzo[b,f]thiepins

  摘要：

  2,6,10-三氯-、2,7,10-三氯-和2,8,10-三氯-10,11-二氢二苯并[b,f]噻吩(Vabc)与1-(2-羟乙基)哌嗪、1-甲基哌嗪和1-苄基哌嗪的取代反应制得了标题化合物IIabc, IIIab和IVab。从2,5-二氯乙酮与2-氯噻吩或3-氯噻吩反应开始，通过6个步骤得到了新的氯化合物Va和Vb。化合物IIabc是非痉挛神经元疗法剂多克西瑟平(I)的6-氯、7-氯和8-氯衍生物。它们几乎没有痉挛活性，不抑制大鼠的阿泼吗啡诱发的刻板行为。化合物IIab在大鼠脑纹状体具有类似氯氮平的多巴胺受体亲和力；化合物IIc的亲和力要高得多。另一方面，只有化合物IIb和IIIa在体内证明了显著的抗多巴胺活性(显著增加大鼠脑纹状体内的高香草酸水平)。

  DOI：

  10.1135/cccc19860156

文献信息

• PROTIVA, M.;DLABAC, A.;VALCHAR, M.;WILDT, S.;CERVENA, I.;SEDIVY, Z., COLLECT. CZECHOSL. CHEM. COMMUN., 1986, 51, N 1, 156-166
  作者：PROTIVA, M.、DLABAC, A.、VALCHAR, M.、WILDT, S.、CERVENA, I.、SEDIVY, Z.

  DOI：——

  日期：——
• LIGANDS THAT TARGET HEPATITIS C VIRUS E2 PROTEIN
  申请人：BALHORN Rodney

  公开号：US20160361311A1

  公开（公告）日：2016-12-15

  Hepatitis C Virus (HCV) infects 200 million individuals worldwide. Although several FDA approved drugs targeting the HCV serine protease and polymerase have shown promising results, there is a need for better drugs that are effective in treating a broader range of HCV genotypes and subtypes without being used in combination with interferon and/or ribavirin. Recently, the crystal structure of the core of the HCV E2 protein (E2c) has been determined, providing structural information that can now be used to target the E2 protein and develop drugs that disrupt the early stages of HCV infection by blocking E2's interaction with different host factors. By targeting sites containing conserved E2 amino acids in the CD81 binding site on HCV E2, one might also be able to develop drugs that block HCV infection in a genotype-independent manner. Using the E2c structure as a template, a structural model of the E2 protein core (residues 421-645) was developed that includes the three amino acid segments that are not present in the E2c crystal structure. Blind docking of a diverse library of 1715 small molecules to this model led to the identification of a set of 34 ligands predicted to bind near conserved amino acid residues involved in the HCV E2:CD81 interaction. Surface plasmon resonance was used to screen the ligand set for binding to recombinant E2 protein, and the best binders were subsequently tested to identify compounds that inhibit the infection of hepatocytes by HCV. One compound, 281816, blocked E2 binding to CD81 and inhibited hepatocyte infection by HCV genotypes 1a, 1b, 2a, 2b, 4a and 6a with IC50's ranging from 2.2 μM to 4.6 μM. Methods are described for preventing or treating HCV infection using small molecule inhibitors such as 281816 that target E2 and disrupt its interactions.
• Potential noncataleptic neuroleptic agents; 2,6-Dichloro-, 2,7-dichloro- and 2,8-dichloro-10-piperazino-10,11-dihydrodibenzo[b,f]thiepins
  作者：Miroslav Protiva、Antonín Dlabač、Martin Valchář、Stanislav Wildt、Irena Červená、Zdeněk Šedivý

  DOI：10.1135/cccc19860156

  日期：——

  Substitution reactions of 2,6,10-trichloro-, 2,7,10-trichloro- and 2,8,10-trichloro-10,11-dihydrodibenzo[b,f]thiepin (Vabc) with 1-(2-hydroxyethyl)piperazine, 1-methylpiperazine and 1-benzylpiperazine gave the title compounds IIabc, IIIab and IVab. The new chloro compounds Va and Vb were obtained in 6 steps starting from reactions of 2,5-dichloroacetophenone with 2-chlorothiophenol or 3-chlorothiophenol. Compounds IIabc are 6-chloro, 7-chloro and 8-chloro derivatives of the noncataleptic neuroleptic agent docloxythepin (I). They are almost devoid of cataleptic activity and do not inhibit the apomorphine stereotypies in rats. Compounds IIab have a clozapine-like affinity to dopaminergic receptors in the rat brain striatum; the affinity of IIc is much higher. On the other hand only compounds IIb and IIIa prove a significant antidopaminergic activity in vivo (increase significantly the homovanillic acid level in the rat brain striatum).

  2,6,10-三氯-、2,7,10-三氯-和2,8,10-三氯-10,11-二氢二苯并[b,f]噻吩(Vabc)与1-(2-羟乙基)哌嗪、1-甲基哌嗪和1-苄基哌嗪的取代反应制得了标题化合物IIabc, IIIab和IVab。从2,5-二氯乙酮与2-氯噻吩或3-氯噻吩反应开始，通过6个步骤得到了新的氯化合物Va和Vb。化合物IIabc是非痉挛神经元疗法剂多克西瑟平(I)的6-氯、7-氯和8-氯衍生物。它们几乎没有痉挛活性，不抑制大鼠的阿泼吗啡诱发的刻板行为。化合物IIab在大鼠脑纹状体具有类似氯氮平的多巴胺受体亲和力；化合物IIc的亲和力要高得多。另一方面，只有化合物IIb和IIIa在体内证明了显著的抗多巴胺活性(显著增加大鼠脑纹状体内的高香草酸水平)。